$2.06
Context Therapeutics is a biotechnology business based in the US. Context Therapeutics shares (CNTX) are listed on the NASDAQ and all prices are listed in US Dollars. Context Therapeutics employs 5 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Context Therapeutics stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
How to buy Context Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CNTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Context Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Context Therapeutics stock price (NASDAQ: CNTX)
Use our graph to track the performance of CNTX stocks over time.Context Therapeutics shares at a glance
Latest market close | $2.09 |
---|---|
52-week range | $0.77 - $2.75 |
50-day moving average | $2.26 |
200-day moving average | $1.57 |
Wall St. target price | $7.63 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.96 |
Is it a good time to buy Context Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Context Therapeutics price performance over time
Historical closes compared with the close of $2.09 from 2024-09-13
1 week (2024-09-09) | -2.34% |
---|---|
1 month (2024-08-16) | -19.92% |
3 months (2024-06-14) | 6.63% |
6 months (2024-03-15) | 91.74% |
1 year (2023-09-15) | 116.58% |
---|---|
2 years (2022-09-16) | 44.14% |
3 years (2021-09-16) | 185 |
5 years (2019-09-16) | 450 |
Context Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -19.19% |
Return on equity TTM | -29.68% |
Profit margin | 0% |
Book value | $1.35 |
Market Capitalization | $160.5 million |
TTM: trailing 12 months
Context Therapeutics share dividends
We're not expecting Context Therapeutics to pay a dividend over the next 12 months.
Context Therapeutics share price volatility
Over the last 12 months, Context Therapeutics's shares have ranged in value from as little as $0.77 up to $2.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Context Therapeutics's is 2.31. This would suggest that Context Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Context Therapeutics's beta into context you can compare it against those of similar companies.
- Soligenix (SNGX.US): 1.836
- Lumos Pharma (LUMO.US): 0.359
Context Therapeutics overview
Context Therapeutics Inc. , a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Frequently asked questions
nullWhat percentage of Context Therapeutics is owned by insiders or institutions?
Currently 2.781% of Context Therapeutics shares are held by insiders and 77.703% by institutions. How many people work for Context Therapeutics?
Latest data suggests 5 work at Context Therapeutics. When does the fiscal year end for Context Therapeutics?
Context Therapeutics's fiscal year ends in December. Where is Context Therapeutics based?
Context Therapeutics's address is: 2001 Market Street, Philadelphia, PA, United States, 19103 What is Context Therapeutics's ISIN number?
Context Therapeutics's international securities identification number is: US21077P1084
More guides on Finder
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Call options explained
Learn the basics of call options: what they are, how they work and examples.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Zacks Trade review 2024
What to expect when you sign up for a Zacks Trade brokerage account.
Ask a question